Xenetic appoints Jeffrey Eisenberg as COO
Mr. Eisenberg is a life science executive with over 20 years of operational experience who has been serving on Xenetic’s Board of Directors since July 2016.
Over the course of his career, Mr. Eisenberg has led all crucial areas of R&D, operations, manufacturing/quality, business development, strategic partnering, product development, commercialization, and talent management.
Prior to joining the Xenetic management team, Mr. Eisenberg has served on the Company’s Board of Directors since July 2016.
Previously, he served at Noven Pharmaceuticals, Inc. for over a decade beginning as Vice President, General Counsel and Corporate Secretary and departing as the President and CEO and a member of the Board of Directors.
As CEO, Mr. Eisenberg led Noven to achieve several notable accomplishments including managing the integration of Noven and Hisamitsu following the acquisition of Noven in 2009.
He also served as Senior Vice President of Strategic Alliances, Interim President and CEO, and Executive Vice President while serving at Noven.
Currently, Mr. Eisenberg serves as a member of the Board of Directors of Mabvax Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative vaccine and monoclonal antibody-based therapeutics for the diagnosis and treatment of cancer.
Mr. Eisenberg graduated from The Wharton School, University of Pennsylvania with his Bachelor of Science degree in Economics and received his Doctor of Law degree from Columbia University Law School in New York. ■
LATEST MOVES FROM Massachusetts
- PTC appoints Corinna Lathan to board
- J.Jill appoints James S. Scully to board
- Raytheon elects Robert O. Work as director
- Xenetic Biosciences appoints three directors
- Insulet appoints two to board
More inside POST